Curative treatment for oligometastatic gastroesophageal cancer– results of a prospective multicenter study
2024

Curative Treatment for Oligometastatic Gastroesophageal Cancer

Sample size: 35 publication 10 minutes Evidence: moderate

Author Information

Author(s): Norén N., Rouvelas I., Lundell L., Nilsson M., Sunde B., Szabo E., Edholm D., Hedberg J., Smedh U., Hermansson M., Lindblad M., Klevebro F.

Primary Institution: Karolinska Institutet

Hypothesis

Can combined systemic and local treatment with curative intent be safely administered to patients with oligometastatic gastroesophageal cancer?

Conclusion

Curative treatment for oligometastatic gastroesophageal cancer is relatively safe, with an overall survival of 20.8 months and no postoperative mortality.

Supporting Evidence

  • 29 out of 35 patients completed the treatment.
  • Postoperative complications occurred in 73.1% of patients, but there was no postoperative mortality.
  • Median overall survival was 20.8 months from diagnosis.

Takeaway

Doctors are trying a new way to treat some stomach and esophagus cancers that have spread, and it seems to help people live longer without dying from surgery.

Methodology

This was a prospective multicenter cohort study involving patients with oligometastatic gastroesophageal cancer who received perioperative chemotherapy followed by surgical resection or liver ablation.

Potential Biases

Potential biases due to the non-randomized nature of the study and missing data.

Limitations

The study had a non-randomized design, a heterogeneous patient group, and a limited sample size.

Participant Demographics

The median age was 66 years, with 65.7% male participants.

Statistical Information

P-Value

0.035

Confidence Interval

11.2–42.6

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s00423-024-03575-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication